Watchlist
RHI · Robert Half Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 18 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Resolved Graded and closed 2026-08-14 at low conviction — the published kill line did not fire. Coverage continued after the close; the read below is dated 2026-09-20 and is not part of the scored record.
Current thesis
White-collar staffing in secular decline: Q2 EPS collapsed to $0.26 (2026-07-23) as AI automation and a frozen hiring market gut permanent-placement demand. The >5% dividend yield reads as a value-trap signal rather than a floor. No accelerating long narrative; a cyclical bounce needs labor data to turn first.
Kill line
A weekly close below $36 confirms the secular staffing downtrend and kills any cyclical-bounce thesis, opening a slide toward Goldman's $29 Sell target; a dividend cut would seal the value-trap read.
Pick status
Played out resolved published kill line did not fire How this is scored →Latest analysis and events for RHI —
As of 20 September 2026, the latest FrontierPicks analysis for Robert Half Inc. (RHI): White-collar staffing in secular decline: Q2 EPS collapsed to $0.26 (2026-07-23) as AI automation and a frozen hiring market gut permanent-placement demand. The >5% dividend yield reads as a value-trap signal rather than a floor. No accelerating long narrative; a cyclical bounce needs labor data to turn first.
Kill line: A weekly close below $36 confirms the secular staffing downtrend and kills any cyclical-bounce thesis, opening a slide toward Goldman's $29 Sell target; a dividend cut would seal the value-trap read.
Next dated event on file: — catalyst in 9d.
Current Thesis
Robert Half's staffing-recovery thesis requires Q3 results to meet July guidance and the shares to recover their September 4 close before the published $36 weekly-close threshold fails. The measurable recovery case is Q3 earnings per share (EPS) of at least $0.43 and revenue of at least $1.310 billion, the lower bounds of management's 2026-07-23 guidance, together with a weekly close above the 2026-09-04 reference close of $42.58. A weekly close below $36 invalidates that case.
The material change since the September 6 assessment is weaker price confirmation: the adjusted close was $37.38 on 2026-09-18, compared with $42.58 on 2026-09-04. The narrative is maturing — an inference anchored to BMO Capital's 2026-07-27 cycle-trough call, subsequent high-dividend coverage on 2026-09-09, and the lower September 18 close. These observations support low conviction in the recovery case; they do not establish permanent industry decline or isolate artificial intelligence as the cause of staffing weakness.
Bullish and bearish views on Robert Half Inc.
The model's bull view on Robert Half Inc. (RHI), in brief: Guidance defines an earnings recovery. Robert Half's 2026-07-23 Q3 guidance called for EPS of $0.43–$0.53 on revenue of $1.310–$1.410 billion, against reported Q2 EPS of $0.26 and revenue of $1.336 billion. Results below either lower bound would contradict the specified recovery… The bear view: Hiring confirmation remains incomplete. The 2026-09-04 employment report described professional and business services employment as little changed, with 10,000 additional jobs in August. July quits were also little changed at 3.1 million in the 2026-09-01 Job Openings and Labor… Both cases follow in full.
Bull Case
- Guidance defines an earnings recovery. Robert Half's 2026-07-23 Q3 guidance called for EPS of $0.43–$0.53 on revenue of $1.310–$1.410 billion, against reported Q2 EPS of $0.26 and revenue of $1.336 billion. Results below either lower bound would contradict the specified recovery case.
- The trough argument remains testable. BMO Capital upgraded Robert Half on 2026-07-27 and raised its analyst target to $47, describing Q2 as the business-cycle low. That is BMO's interpretation; the Q3 results provide the next company-level test.
- Temporary employment supplied limited support. The Bureau of Labor Statistics (BLS) reported 6,800 additional temporary-help jobs in August on 2026-09-04. That observation is consistent with stabilization, but the sample is too small to establish a staffing recovery.
Bear Case
- Hiring confirmation remains incomplete. The 2026-09-04 employment report described professional and business services employment as little changed, with 10,000 additional jobs in August. July quits were also little changed at 3.1 million in the 2026-09-01 Job Openings and Labor Turnover Survey (JOLTS); neither release established accelerating labor turnover. BLS JOLTS release
- The payout exceeds quarterly earnings. The board's 2026-08-03 declaration specified a $0.59 quarterly dividend per share, payable 2026-09-15, against Q2 EPS of $0.26 reported on 2026-07-23. This comparison establishes an earnings-coverage gap for that quarter; it does not establish how the payment was funded or predict a reduction.
- Analyst disagreement remains substantial. Goldman Sachs retained its negative rating and a $29 analyst target on 2026-07-24, while BMO Capital published its $47 target on 2026-07-27. Those dated assessments describe different recovery expectations, not a current consensus or evidence of investor flows.
Setup & Price Structure
The split- and dividend-adjusted series records a $37.38 close on 2026-09-18, 17.6% below its $45.34 trailing-year high, while the three-month price change remained positive at 30.1%. The 14-day relative strength index (RSI) was 15.2 index points on that date. These measurements show weak recent momentum within a still-positive three-month comparison; the low RSI alone does not establish a reversal.
The $36 threshold retains the research invalidation published on 2026-09-06; it is not presented as a newly verified support shelf. The latest supplied close remains above it. The September 4 close of $42.58 supplies a dated recovery benchmark, rather than a claim that resistance has been statistically established.
Benzinga included Robert Half in high-dividend industrial-stock coverage on 2026-09-09 and quoted a dividend yield of 6.02% at that time. That is an observable income-oriented coverage event, not a current yield calculation. The available coverage sample is too small to establish retail crowding, and no dated fund-flow, short-interest, insider-transaction or issuance evidence supports a positioning conclusion.
Catalyst Calendar (next 30 days)
- 2026-09-29 — August JOLTS release. The BLS calendar confirms this date, replacing the earlier October estimate. Hiring and quits provide the next observations against the little-changed July readings released on 2026-09-01. BLS September calendar
- 2026-10-02 — September employment report. The BLS schedules the release for this date. Professional and business services and temporary-help employment provide the relevant comparisons with the August readings published on 2026-09-04. BLS release schedule
- ~2026-10-28, estimated — Q3 results. This later event is included because it directly tests the 2026-07-23 guidance. MarketBeat estimates October 28, while Investing.com lists October 27; a company-confirmed date has not been established. Revenue below $1.310 billion or EPS below $0.43 would contradict the stated recovery case. MarketBeat earnings calendar, Investing.com earnings calendar
What Would Change Our Mind
Failure of the recovery structure is defined by a weekly close below $36, retaining the threshold published on 2026-09-06. A Q3 result below either lower bound of the July guidance would separately undermine BMO's July trough interpretation. A subsequent dividend declaration below the $0.59 per share announced on August 3 would weaken the income argument without proving secular decline.
Conversely, Q3 results meeting both guidance floors together with a weekly close above the September 4 reference close of $42.58 would satisfy the specified recovery case, provided the $36 weekly-close invalidation had not already occurred. Revenue attribution and segment results would still be needed to distinguish hiring recovery from other sources of earnings improvement.
Correlation Notes
This remains a single-name staffing-recovery assessment. The 2026-09-04 employment report showed 162,000 additional nonfarm jobs overall but only 10,000 in professional and business services, illustrating why the headline labor number cannot substitute for the relevant industry series.
No matched peer-return series or correlation estimate accompanies the 2026-09-18 price observations. A staffing-group rally, an interest-rate relationship and exposure to an artificial-intelligence infrastructure theme therefore remain unmeasured; none supplies confirmation for this thesis.
Notes
- Dividend is $0.59/quarter (declared 2026-08-03, record 2026-08-25, payable 2026-09-15) against Q2 2026 EPS of $0.26; payout coverage is worth re-checking at each declaration.
- Robert Half announces its earnings date roughly a week ahead (the Q2 date was announced 2026-07-16), so the ~2026-10-21 Q3 date is an estimate until confirmed.
- Sell-side dispersion is unusually wide: published targets have run from $20 (McVeigh, Sell) to $50 (Truist, 2026-07-22), with Goldman at $29 (2026-07-24) and BMO at $47 (2026-07-27).
- Protiviti leadership transition effective 2027-01-01: Cory Gunderson becomes president and CEO, Joe Tarantino moves to senior managing director (announced 2026-08-03).
- BLS labor releases are the main dated inputs between company prints; JOLTS dates beyond the confirmed 2026-10-02 employment situation remain estimates.
Related · shared themes
OSCR
Oscar Health, Inc.
Oscar Health's higher earnings outlook and quantified 2027 pricing support a post-Investor-Day rerating. A weekly close above $32.76 before a weekly close below $29.83 would complete the price-confirmation test; the September 18, 2026 close of $32.13 leaves it unresolved.
CNC
Centene Corporation
Centene's margin-repair case requires sustained earnings guidance and a weekly close above $68.72 by its 2026-10-27 results. September's reaffirmation supports the earnings leg, but a weekly close below $65 or withdrawal or reduction of fiscal 2026 adjusted EPS guidance above $4.80 invalidates the case.
HNGE
Hinge Health, Inc.
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
HUM
Humana Inc.
Humana's Medicare Advantage margin-recovery story faces a renewed price test: an adjusted daily close above $409.80 before a daily close below $383. The September 1, 2026 earnings reaffirmation supports stability, while October Star Ratings test the quality-bonus premise.
See also · stocks to watch